Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2013

Taiwan Research Center Looks to Icon to Manage Clinical Trials

  • The National Clinical Trials and Research Center (NCTRC) at the National Taiwan University Hospital has tapped Icon, a CRO founded in Dublin in 1990, to help it enhance the set-up and management of clinical studies in Taiwan.

    Per the agreement, NCTRC and Icon will work together on study start-up, site feasibility, key site and investigator selection, and patient recruitment. Both organizations will also be working together to enhance clinical research standards in Taiwan.

    "Our customers are increasingly looking to include Taiwan in their clinical programs and are expecting fast timelines for study start-up and patient recruitment," said Wei Ming Goh, Icon’s vp, Asia-Pacific, in a statement. "By combining the proven expertise of Icon and NCTRC in the region, we can further accelerate study timelines which will benefit our customers and also enhance the Taiwanese clinical trials industry."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »